Fax: (215) 214-1629
Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant radiation and tamoxifen†
Article first published online: 23 OCT 2006
Copyright © 2006 American Cancer Society
Volume 107, Issue 11, pages 2552–2558, 1 December 2006
How to Cite
Freedman, G. M., Anderson, P., Li, T., Ross, E., Swaby, R. and Goldstein, L. (2006), Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant radiation and tamoxifen. Cancer, 107: 2552–2558. doi: 10.1002/cncr.22291
Presented in abstract form at the Scientific Session of the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Denver, Colorado, October 16–20, 2005.
- Issue published online: 17 NOV 2006
- Article first published online: 23 OCT 2006
- Manuscript Accepted: 8 SEP 2006
- Manuscript Revised: 1 SEP 2006
- Manuscript Received: 31 JUL 2006
- 4GreeneFL, PageDL, FlemingID, et al., editors. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
- 5Cancer of the breast. In: WangCC, editor. Clinical Radiation Oncology: Indications, Techniques and Results. 2nd ed. New York: Wiley-Liss; 2000., .
- 6National Comprehensive Cancer Network. NCCN practice guidelines for breast cancer. 2005. Available at URL: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf [accessed August 31, 2006].
- 8Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol. 2000; 18: 2718–2727., , , et al.
- 9United States Department of Health and Human Services. Bone Health and Osteoporosis. A Report of the Surgeon General. Washington, DC: Government Printing Office; 2004.